代表性论著：

2023

1.Wang J, Zhang J, Wang J, Hu X, Ouyang L*, Wang Y*. Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics. J Med Chem. 2023;66(10):6437-6462. doi: 10.1021/acs.jmedchem.2c01655IF: 7.3 Q1 B1

2.Li Y, Liu Y, Zhang D, Chen J, Yang G, Tang P, Yang C, Liu J, Zhang J, Ouyang L*. Discovery, Synthesis, and Evaluation of Novel Dual Inhibitors of a Vascular Endothelial Growth Factor Receptor and Poly(ADP-Ribose) Polymerase for BRCA Wild-Type Breast Cancer Therapy. J Med Chem. 2023;66(17):12069-12100. doi: 10.1021/acs.jmedchem.3c00640IF: 7.3 Q1 B1. 

3.Zhang L, Zhen Y, Feng L, Li Z, Lu Y, Wang G, Ouyang L*. Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer. Eur J Med Chem. 2023;259:115648. doi: 10.1016/j.ejmech.2023.115648IF: 6.7 Q1 B1. 

4.Tang W, Lin C, Yu Q, Zhang D, Liu Y, Zhang L, Zhou Z, Zhang J, Ouyang L*. Novel Medicinal Chemistry Strategies Targeting CDK5 for Drug Discovery. J Med Chem. 2023;66(11):7140-7161. doi: 10.1021/acs.jmedchem.3c00566IF: 7.3 Q1 B1. 

5.Pei J, Wang G, Wang A, Wu C, Pan X, Shuai W, Bu F, Zhu Y, Wang Y, Ouyang L*, Li W. Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell 6.Lung Cancer. J Med Chem. 2023;66(8):5719-5752. doi: 10.1021/acs.jmedchem.3c00027IF: 7.3 Q1 B1.

6.Wang G, Wu Y, Wu C, Shuai W, Jiang T, Wang A, Bu F, Sun Q, Ouyang L*. Rational design and crystallographic analysis of novel isoform-selective TRKA inhibitors for cancer therapy. Acta Pharm Sin B. 2023;13(1):440-443. doi: 10.1016/j.apsb.2022.10.012IF: 14.5 Q1 B1. 

7.Tan L, Wu C, Zhang J, Yu Q, Wang X, Zhang L, Ge M, Wang Z, Ouyang L*, Wang Y*. Design, Synthesis, and Biological Evaluation of Heterocyclic-Fused Pyrimidine Chemotypes Guided by X-ray Crystal Structure with Potential Antitumor and Anti-multidrug Resistance Efficacy Targeting the Colchicine Binding Site. J Med Chem. 2023;66(5):3588-3620. doi: 10.1021/acs.jmedchem.2c02115IF: 7.3 Q1 B1 .

8.Shuai W, Bu F, Zhu Y, Wu Y, Xiao H, Pan X, Zhang J, Sun Q, Wang G, Ouyang L*. Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease. J Med Chem. 2023;66(2):1273-1300. doi: 10.1021/acs.jmedchem.2c01410IF: 7.3 Q1 B1. 

2022

9.Feng L, Wang G, Chen Y, He G, Liu B, Liu J, Chiang CM, Ouyang L*. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Med Res Rev. 2022;42(2):710-743. doi: 10.1002/med.21859IF: 13.3 Q1 B1. 

10.Lin C, Chen Y, Zhu M, Pei J, Zhou Y, Gou M, Ouyang L*. A sulfhydryl blocking reagent BT-4 sensitizes cisplatin-based micelle prodrugs for efficient treatment of breast cancer. Int J Pharm. 2022;626:122187. doi: 10.1016/j.ijpharm.2022.122187IF: 5.8 Q1 B2. 

11.Zhan P, Yu B, Ouyang L*. Drug repurposing: An effective strategy to accelerate contemporary drug discovery. Drug Discov Today. 2022;27(7):1785-1788. doi: 10.1016/j.drudis.2022.05.026IF: 7.4 Q1 B2. 

12.Pan X, Pei J, Wang A, Shuai W, Feng L, Bu F, Zhu Y, Zhang L, Wang G, Ouyang L*. Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy. Acta Pharm Sin B. 2022;12(5):2171-2192. doi: 10.1016/j.apsb.2021.12.022IF: 14.5 Q1 B1. 

13.Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, Liu J, Ouyang L*. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy. J Med Chem. 2022;65(9):6803-6825. doi: 10.1021/acs.jmedchem.2c00135IF: 7.3 Q1 B1. 

14.Chen J, Tang P, Wang Y, Wang J, Yang C, Li Y, Yang G, Wu F, Zhang J, Ouyang L*. Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development. J Med Chem. 2022;65(7):5184-5211. doi: 10.1021/acs.jmedchem.1c01835IF: 7.3 Q1 B1. 

15.Tan L, Zhang J, Wang Y, Wang X, Wang Y, Zhang Z, Shuai W, Wang G, Chen J, Wang C, Ouyang L*, Li W. Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. J Med Chem. 2022;65(7):5149-5183. doi: 10.1021/acs.jmedchem.1c01714IF: 7.3 Q1 B1. 

16.Zhu Y, Shuai W, Zhao M, Pan X, Pei J, Wu Y, Bu F, Wang A, Ouyang L*, Wang G*. Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases. J Med Chem. 2022;65(5):3758-3775. doi: 10.1021/acs.jmedchem.1c01947IF: 7.3 Q1 B1. 

17.Bu F, Zhang J, Shuai W, Liu J, Sun Q, Ouyang L*. Repurposing drugs in autophagy for the treatment of cancer: From bench to bedside. Drug Discov Today. 2022;27(7):1815-1831. doi: 10.1016/j.drudis.2021.11.013IF: 7.4 Q1 B2. 

2021

18.Zhang J, Tang P, Zou L, Zhang J, Chen J, Yang C, He G, Liu B, Liu J, Chiang CM, Wang G, Ye T, Ouyang L*. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy. J Med Chem. 2021;64(24):18025-18053. doi: 10.1021/acs.jmedchem.1c01382IF: 7.3 Q1 B1. 

19.Zhang L, Zhang L, Guo Y, Xiao M, Feng L, Yang C, Wang G, Ouyang L*. MCDB: A comprehensive curated mitotic catastrophe database for retrieval, protein sequence alignment, and target prediction. Acta Pharm Sin B. 2021;11(10):3092-3104. doi: 10.1016/j.apsb.2021.05.032IF: 14.5 Q1 B1. 

20.Lin C, Gao H, Ouyang L*. Advance cardiac nanomedicine by targeting the pathophysiological characteristics of heart failure. J Control Release. 2021;337:494-504. doi: 10.1016/j.jconrel.2021.08.002IF: 10.8 Q1 B1. 

21.Xu T, Zhang J, Yang C, Pluta R, Wang G, Ye T, Ouyang L*. Identification and optimization of 3-bromo-N'-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer. Eur J Med Chem. 2021;219:113424. doi: 10.1016/j.ejmech.2021.113424IF: 6.7 Q1 B1. 

22.Li Y, Yang G, Yang C, Tang P, Chen J, Zhang J, Liu J, Ouyang L*. Targeting Autophagy-Related Epigenetic Regulators for Cancer Drug Discovery. J Med Chem. 2021;64(16):11798-11815. doi: 10.1021/acs.jmedchem.1c00579IF: 7.3 Q1 B1. 

23.Li Y, Yang G, Zhang J, Tang P, Yang C, Wang G, Chen J, Liu J, Zhang L, Ouyang L*. Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer. J Med Chem. 2021;64(16):12022-12048. doi: 10.1021/acs.jmedchem.1c00678IF: 7.3 Q1 B1. 

24.Tang P, Zhang J, Liu J, Chiang CM, Ouyang L*. Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. J Med Chem. 2021;64(5):2419-2435. doi: 10.1021/acs.jmedchem.0c01487IF: 7.3 Q1 B1. 

25.Liao M, Zhang J, Wang G, Wang L, Liu J, Ouyang L*, Liu B*. Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions. J Med Chem. 2021;64(5):2382-2418. doi: 10.1021/acs.jmedchem.0c01180IF: 7.3 Q1 B1. 

26.Pei J, Pan X, Wang A, Shuai W, Bu F, Tang P, Zhang S, Zhang Y, Wang G, Ouyang L*. Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy. Chem Commun (Camb). 2021;57(97):13194-13197. doi: 10.1039/d1cc04661fIF: 4.9 Q2 B2. 

27.Pei J, Wang G, Feng L, Zhang J, Jiang T, Sun Q, Ouyang L*. Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery. J Med Chem. 2021 Apr 8;64(7):3493-3507. doi: 10.1021/acs.jmedchem.0c01689IF: 7.3 Q1 B1. 

28.Yang C, Zhang J, Liao M, Yang Y, Wang Y, Yuan Y, Ouyang L*. Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy. Drug Discov Today. 2021;26(3):817-825. doi: 10.1016/j.drudis.2020.12.006IF: 7.4 Q1 B2. 

29.Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J, Chen Y, Ouyang L*. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharm Sin B. 2021;11(2):355-372. doi: 10.1016/j.apsb.2020.05.004IF: 14.5 Q1 B1. 

30.Chang X, Sun D, Shi D, Wang G, Chen Y, Zhang K, Tan H, Liu J, Liu B, Ouyang L*. Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy. Acta Pharm Sin B. 2021;11(1):156-180. doi: 10.1016/j.apsb.2020.06.003IF: 14.5 Q1 B1. 

2020

31.Chen Y, Wang G, Ouyang L*. Promising inhibitors targeting Mpro: an ideal strategy for anti-SARS-CoV-2 drug discovery. Signal Transduct Target Ther. 2020;5(1):173. doi: 10.1038/s41392-020-00291-8IF: 39.3 Q1 B1. 

32.Wang G, Zhao Y, Liu Y, Sun D, Zhen Y, Liu J, Fu L, Zhang L, Ouyang L*. Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types. J Med Chem. 2020;63(8):3976-3995. doi: 10.1021/acs.jmedchem.9b01896IF: 7.3 Q1 B1. 

33.Xiang H, Zhang J, Lin C, Zhang L, Liu B, Ouyang L*. Targeting autophagy-related protein kinases for potential therapeutic purpose. Acta Pharm Sin B. 2020;10(4):569-581. doi: 10.1016/j.apsb.2019.10.003IF: 14.5 Q1 B1.  

【代表性专利（第一发明人）】

1、CN202111046514.7.

2、CN202110617650.0.

3、CN202010039345.3.

4、CN202010877378.5.

5、CN108218814A.

6、CN107987054A.

7、CN107903185A.

8、CN106905347B.

9、CN106748892B.

10、CN106478550B.

11、CN106117176B.

12、PCT/CN2018/072575